Biomaterials for direct cardiac repair—A rapid scoping review 2012–2022
Source abstract
Abstract
A plethora of biomaterials for heart repair are being tested worldwide for potential clinical application. These therapeutics aim to enhance the quality of life of patients with heart disease using various methods to improve cardiac function. Despite the myriad of therapeutics tested, only a minority of these studied biomaterials have entered clinical trials. This rapid scoping review aims to analyze literature available from 2012 to 2022 with a focus on clinical trials using biomaterials for direct cardiac repair, i.e., where the intended function of the biomaterial is to enhance the repair of the endocardium, myocardium, epicardium or pericardium. This review included neither biomaterials related to stents and valve repair nor biomaterials serving as vehicles for the delivery of drugs. Surprisingly, the literature search revealed that only 8 different biomaterials mentioned in 23 different studies out of 7038 documents (journal articles, conference abstracts or clinical trial entries) have been tested in clinical trials since 2012. All of these, intended to treat various forms of ischaemic heart disease (heart failure, myocardial infarction), were of natural origin and most used direct injections as their delivery method. This review thus reveals notable gaps between groups of biomaterials tested pre-clinically and clinically. STATEMENT OF SIGNIFICANCE: Rapid scoping review of clinical application of biomaterials for cardiac repair. 7038 documents screened; 23 studies mention 8 different biomaterials only. Biomaterials for repair of endocardium, myocardium, epicardium or pericardium. Only 8 different biomaterials entered clinical trials in the past 10 years. All of the clinically translated biomaterials were of natural origin.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Tissue Engineering and Regenerative Medicine · Cardiac Structural Anomalies and Repair
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (86)
Show source-provided references
1. Heart disease and stroke statistics—2023 update: a report from the American heart association10.1161/CIR.0000000000001123 ↗
2. Cell therapy in patients with heart failure: a comprehensive review and emerging concepts10.1093/cvr/cvab135 ↗
3. Healing the Ischaemic heart: a critical review of stem cell therapies
4. Nanomedicines for cardiovascular disease10.1038/s44161-023-00232-y ↗
5. X. Hao, Q. Li, Recent Advances in cell-based nanotherapy for cardiovascular diseases, Macromol. Biosci. n/a(n/a) 2200537. 10.1002/mabi.202200537.
6. Nanotechnology in interventional cardiology: a state-of-the-art review
7. Nanoengineered sprayable therapy for treating myocardial infarction10.1021/acsnano.1c08890 ↗
8. Therapeutic use of bioengineered materials for myocardial infarction
9. Electroconductive biomaterials for cardiac tissue engineering10.1016/j.actbio.2021.08.031 ↗
10. Recent advances in designing electroconductive biomaterials for cardiac tissue engineering10.1002/adhm.202200055 ↗
11. Macrophage polarization in cardiac tissue repair following myocardial infarction10.3390/ijms22052715 ↗
12. Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction10.1038/s41467-019-12748-8 ↗
13. Recombinant human collagen hydrogel rapidly reduces methylglyoxal adducts within cardiomyocytes and improves borderzone contractility after myocardial infarction in mice10.1002/adfm.202204076 ↗
14. Combined methylglyoxal scavenger and collagen hydrogel therapy prevents adverse remodeling and improves cardiac function post-myocardial infarction10.1002/adfm.202108630 ↗
15. Therapies to prevent post-infarction remodelling: from repair to regeneration10.1016/j.biomaterials.2021.120906 ↗
16. Chapter 11: scoping reviews (2020 version)
17. Undertaking a scoping review: a practical guide for nursing and midwifery students, clinicians, researchers, and academics10.1111/jan.14743 ↗
18. PRESS peer review of electronic search strategies: 2015 guideline statement10.1016/j.jclinepi.2016.01.021 ↗
19. Higgins · 2011
20. Effectiveness of biatrial epicardial application of amiodarone-releasing adhesive hydrogel to prevent postoperative atrial fibrillation10.1016/j.jtcvs.2014.05.049 ↗
21. Epicardial application of hydrogel with amiodarone for prevention of postoperative atrial fibrillation in patients after coronary artery bypass grafting10.1007/s12265-019-09905-1 ↗
22. Local use of hydrogel with amiodarone in cardiac surgery: experiment and translation to the clinic10.3390/gels7010029 ↗
23. The randomised study of epicardial application of hydrogel with amiodarone for prevention of postoperative atrial fibrillation in patients after coronary artery bypass grafting10.1093/eurheartj/ehz748.0122 ↗
24. Clinical efficacy of epicardial application with an optimal dosage of amiodarone-releasing hydrogels to prevent postoperative atrial fibrillation10.1016/j.jacc.2016.07.462 ↗
25. Clinical efficacy of epicardial application of drug-releasing hydrogels to prevent postoperative atrial fibrillation10.1016/j.jtcvs.2015.06.061 ↗
26. Kyoto University Graduate School of Medicine, Clinical trial on the safety of myocardium regenerative therapy for ischemic heart disease using biodegradable polymeric carrier and basic fibroblast growth factor, 2015. https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000021508.
27. Rao · Am. Heart J. · 2015 · 170 · 92910.1016/j.ahj.2015.08.017 ↗
28. Algisyl-LVR TM with coronary artery bypass grafting reduces left ventricular wall stress and improves function in the failing human heart10.1016/j.ijcard.2013.01.003 ↗
29. G. Cristian, S.I. Dumitrescu, I. Droc, I. Mocanu, V. Murgu, D. Savoiu, M. Crisan, D. Dragomir, S. Stamate, Effect of left ventricular augmentation with Algysil-LVR device, 16 (2014) 51.
30. L. Menicanti, I. Mocanu, F. Miraldi, S. Marasco, A. Hinson, R.J. Lee, H.N. Sabbah, D.L. Mann, Safety of a novel surgical therapy for the treatment of advanced heart failure: review of surgical morbidity and mortality of algisyl-LVR from the augment-HF trial, 19 (2014) S68.10.1093/icvts/ivu276.228 ↗
31. LoneStar Heart Inc, A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure, 2014. https://ClinicalTrials.gov/show/NCT01311791.
32. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial)10.1093/eurheartj/ehv259 ↗
33. S. Dumitrescu, I. Droc, G. Neagoe, I. Mocanu, V. Murgu, D. Savoiu, I. Crisan, D. Dragomir, S.C. Stamate, G. Cristian, Effect of left ventricular augmentation with alginate biopolymer on right heart function, 16 (2015) ii131.
34. The feasibility and safety of Algisyl-LVR TM as a method of left ventricular augmentation in patients with dilated cardiomyopathy: initial first in man clinical results10.1016/j.ijcard.2015.06.111 ↗
35. D. Mann, S.D. Anker, A. Coats, M. Volterrani, H.N. Sabbah, R. Dowling, R.J. Lee, A. Hinson, Follow-up results from AUGMENT-HF: a multicenter randomized controlled clinical trial of the efficacy of left ventricular augmentation with algisyl-LVR in the treatment of heart failure, 21(11) (2015) 936.10.1016/j.cardfail.2015.09.008 ↗
36. One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure10.1002/ejhf.449 ↗
37. Effect of left ventricular augmentation with Algysil-LVR device: 12 month follow-up, in Rapid Fire Abstract session - Up-to-date research on left ventricular function
38. A. Govea, Q. Fang, T. Walters, P. Janaswamy, B. Nazer, A. Qasim, N.B. Schiller, R.J. Lee, LV augmentation with algisyl hydrogel improves ventricular arrhythmias in patients with cardiomyopathy, 14(5) (2017) S128.
39. LoneStar Heart Inc, A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure, 2020. https://ClinicalTrials.gov/show/NCT03082508.
40. Xijing Hospital, First in Man Study of Implantable Alginate Hydrogel, 2022. https://ClinicalTrials.gov/show/NCT04781660.
41. Intracoronary delivery of injectable bioabsorbable scaffold (IK-5001) to treat left ventricular remodeling after ST-elevation myocardial infarction: a first-in-man study10.1161/CIRCINTERVENTIONS.114.001478 ↗
42. Bellerophon Bcm Llc, IK-5001 for the prevention of remodeling of the ventricle and congestive heart failure after acute myocardial infarction, 2015. https://ClinicalTrials.gov/show/NCT01226563.
43. Bioabsorbable intracoronary matrix for prevention of ventricular remodeling after myocardial infarction10.1016/j.jacc.2016.05.053 ↗
44. Inova Health Systems, CorMatrix ECM Study: to Identify Inflammatory Markers Following CABG With/Without ECM (CorMatrix), 2012. https://classic.clinicaltrials.gov/ct2/show/NCT01535807.
45. University of Calgary, CorMatrix Cardiovascular Inc, Epicardial Infarct Repair Using CorMatrix®-ECM: Clinical Feasibility Study, 2017. https://ClinicalTrials.gov/show/NCT02887768.
46. Ventrix Inc, A Study of VentriGel in Post-MI Patients, 2018. https://ClinicalTrials.gov/show/NCT02305602.
47. First-in-man study of a cardiac extracellular matrix hydrogel in early and late myocardial infarction patients10.1016/j.jacbts.2019.07.012 ↗
48. Effect of intramyocardial grafting collagen scaffold with mesenchymal stromal cells in patients with chronic ischemic heart disease: a randomized clinical trial10.1001/jamanetworkopen.2020.16236 ↗
49. T. Naofumi, AutoLogous Human CArdiac-Derived Stem Cell to Treat Ischemic cArdiomyopathy (ALCADIA), 2013. https://ClinicalTrials.gov/show/NCT00981006.
50. Assistance Publique - Hôpitaux de Paris, Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure, 2018. https://ClinicalTrials.gov/show/NCT02057900.
51. Angiogenic biomaterials to promote therapeutic regeneration and investigate disease progression10.1016/j.biomaterials.2020.120207 ↗
52. Naturally-derived biomaterials for tissue engineering applications10.1007/978-981-13-0947-2_23 ↗
53. Alginate for cardiac regeneration: from seaweed to clinical trials
54. Introduction to alginate: biocompatible, biodegradable, antimicrobial nature and various applications
55. Crunchbase Inc, 2023. https://www.crunchbase.com/organization/lonestar-heart.
56. Cardiac cell therapy for heart repair: should the cells be left out?10.3390/cells10030641 ↗
57. Progress in biomaterials for cardiac tissue engineering and regeneration10.3390/polym15051177 ↗
58. Stem cell legislation and its impact on the geographic preferences of stem cell researchers10.1007/s40821-021-00182-0 ↗
59. Advances in research on the bioactivity of alginate oligosaccharides10.3390/md18030144 ↗
60. Intracoronary injection of in situ forming alginate hydrogel reverses left ventricular remodeling after myocardial infarction in Swine10.1016/j.jacc.2009.06.010 ↗
61. Abstract 4050: circumferential mid-ventricular intramyocardial injections of alginate hydrogel improve left ventricular function and prevent progressive remodeling in dogs with chronic heart failure
62. Augmentation of left ventricular wall thickness with alginate hydrogel implants improves left ventricular function and prevents progressive remodeling in dogs with chronic heart failure10.1016/j.jchf.2013.02.006 ↗
63. Polymer-based restoration of left ventricular mechanics10.3727/096368911X637461 ↗
64. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat10.1161/CIRCULATIONAHA.107.727420 ↗
65. Acellular bioscaffolds redirect cardiac fibroblasts and promote functional tissue repair in rodents and humans with myocardial injury10.1038/s41598-020-66327-9 ↗
66. Evidence for mechanisms underlying the functional benefits of a myocardial matrix hydrogel for post-MI treatment10.1016/j.jacc.2015.12.035 ↗
67. Gelatin hydrogel enhances the engraftment of transplanted cardiomyocytes and angiogenesis to ameliorate cardiac function after myocardial infarction10.1371/journal.pone.0133308 ↗
68. Fibrin matrices as (injectable) biomaterials: formation, clinical use, and molecular engineering10.1002/mabi.201900283 ↗
69. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction10.1016/j.jacc.2017.11.047 ↗
70. Human embryonic stem cells: derivation, maintenance and cryopreservation10.15283/ijsc.2011.4.1.9 ↗
71. Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure10.1016/j.healun.2016.01.013 ↗
72. Evaluation of coronary stents: a review of types, materials, processing techniques, design, and problems10.1016/j.heliyon.2023.e13575 ↗
73. Cardiovascular stents: a review of past, current, and emerging devices
74. Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity10.1038/s41569-020-0422-8 ↗
75. Polymeric prosthetic heart valves: a review of current technologies and future directions10.3389/fcvm.2023.1137827 ↗
76. The role of extracellular matrix (ECM) adhesion motifs in functionalised hydrogels10.3390/molecules28124616 ↗
77. Direct grafting of RGD-motif-containing peptide on the surface of polycaprolactone films10.1163/156856206776986288 ↗
78. Biocompatible electrospun polycaprolactone-polyaniline scaffold treated with atmospheric plasma to improve hydrophilicity10.3390/bioengineering8020024 ↗
79. Hydrogels for tissue engineering: scaffold design variables and applications10.1016/S0142-9612(03)00340-5 ↗
80. Myocardial stiffness evaluation using noninvasive shear wave imaging in healthy and hypertrophic cardiomyopathic adults10.1016/j.jcmg.2018.02.002 ↗
81. Collagen, stiffness, and adhesion: the evolutionary basis of vertebrate mechanobiology10.1091/mbc.E19-12-0709 ↗
82. Polymer-based nanofiber-nanoparticle hybrids and their medical applications10.3390/polym14020351 ↗
83. New forms of electrospun nanofibers applied in cardiovascular field
84. Development of conductive polymeric nanofiber patches for cardiac tissue engineering application10.1002/app.52757 ↗
85. Biomaterials and heart recovery: cardiac repair, regeneration and healing in the MCS era: a state of the “heart10.21037/jtd.2018.01.85 ↗
86. Intramyocardial injection of hydrogel with high interstitial spread does not impact action potential propagation10.1016/j.actbio.2015.08.004 ↗